Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial

BACKGROUND: The randomized phase 3 LYM3001 trial in relapsed follicular lymphoma (FL) demonstrated higher overall (ORR) and complete response (CR) rates and prolonged progression-free survival (PFS) with bortezomib-rituximab versus rituximab. We report findings in high-risk patients (FL Internationa...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Zinzani, Pier Luigi, Khuageva, Nuriet K, Wang, Huaqing, Garicochea, Bernardo, Walewski, Jan, Van Hoof, Achiel, Soubeyran, Pierre, Caballero, Dolores, Buckstein, Rena, Esseltine, Dixie-Lee, Theocharous, Panteli, Enny, Christopher, Zhu, Eugene, Elsayed, Yusri A, Coiffier, Bertrand
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2012
Teme:
Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3502148/
https://ncbi.nlm.nih.gov/pubmed/23088650
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1756-8722-5-67
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki